发明名称 Methods for treating HCV
摘要 The present invention features interferon-free therapies for the treatment of HCV. Preferably, the treatment is over a shorter duration, such as no more than 12 weeks. In one aspect, the therapies comprise administering at least two direct acting antiviral agents and ribavirin to a subject with HCV infection. For example, the therapies comprise administering to the subject effective amounts of therapeutic agent 1, therapeutic agent 2 (or therapeutic agent 3), an inhibitor of cytochrome P450 (e.g., ritonavir), and ribavirin.
申请公布号 US8853176(B2) 申请公布日期 2014.10.07
申请号 US201213656024 申请日期 2012.10.19
申请人 AbbVie Inc. 发明人 Bernstein Barry M.;Menon Rajeev M.;Khatri Amit;Mensing Sven;Dutta Sandeep;Cohen Daniel E.;Podsadecki Thomas J.;Brun Scott C.;Awni Walid M.;Dumas Emily O.;Klein Cheri E.
分类号 A01N43/04;A61K31/70;A61K31/4725;A61K31/497;A61K31/4178;A61K31/513;A61K31/5377;A61K31/4709;A61K31/4025 主分类号 A01N43/04
代理机构 代理人 Zhang Xu
主权项 1. A method of treatment for HCV, comprising administering at least two direct acting antiviral agents (DAAs) and ribavirin to an HCV patient, wherein said treatment does not include administration of interferon to said patient, and said treatment lasts for 12 weeks, wherein said at least two DAAs comprise (1) Compound 1 or a pharmaceutically acceptable salt thereof and (2) Compound 4 or a pharmaceutically acceptable salt thereof, wherein Compound 1 or the salt thereof is co-administered with ritonavir, and wherein said patient is a treatment-naïve patient infected with HCV genotype 2.
地址 North Chicago IL US